No Data
No Data
Chardan Capital Upgrades Adverum Biotechnologies(ADVM.US) to Buy Rating
Press Release: Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as It Prepares to Initiate Pivotal Program
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $20
Zacks.com Featured Highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
Analysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA) and Travere Therapeutics (TVTX)